Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519135 | 1.00 | TSHR (0.53) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| Hydrochloric Acid SCHEMBL7002372 | 0.98 | TSHR (0.52) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL1248188 | 0.83 | AKR1B1 (0.56) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL2049683 | 0.81 | TSHR (0.53) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL5607122 | 0.81 | TSHR (0.53) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL16067 | 0.80 | HSD11B1 (0.47) | TSHRAKR1B1LMNAPGRALDH1A1 | |
| SCHEMBL9579955 | 0.79 | TSHR (0.48) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL11159231 | 0.79 | TSHR (0.52) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL2633428 | 0.79 | MCOLN3 (0.53) | TSHRMCOLN3PTGES2AKR1B1KMT2A | |
| SCHEMBL742940 | 0.79 | PTGES2 (0.64) | TSHRMCOLN3PTGES2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640064-A | Synthesis method of 4' -chloro-2-aminobiphenyl | 山东京博农化科技股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| WO-2013102936-A1 | N-(3-((DIETHYLAMINO) METHYL)-4-HYDROXYPHENYL)-N-(QUINOLIN-4-YL) SULFONAMIDES FOR THE TREATMENT OF TUBERCULOSIS AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-11 | — | — | WO | claimed |
| WO-2007035154-A1 | NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIV DE MONTREAL (CA) | 2026-05-21 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4644375-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-11-05 | — | — | EP | disclosed |
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2025-10-16 | — | — | US | disclosed |
| US-12404248-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-0153874-A2 | Cephalosporin intermediates and their preparation | THE UPJOHN COMPANY (US) | 1985-09-04 | — | — | EP | disclosed |
| US-4507315-A | Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions | MAY & BAKER LIMITED (GB) | 1985-03-26 | — | — | US | disclosed |
| EP-0027906-B1 | PROCESS FOR PREPARING SULPHON AMIDES | BAYER AG (DE) | 1983-05-25 | — | — | EP | disclosed |
| EP-0027906-A1 | Process for preparing sulphon amides | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| US-RE29577-E | Anthraquinone dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |
| US-4060549-A | Process for preparing sulfonic acid fluorides | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
| US-3963763-A | Anthraquinone dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-15 | — | — | US | disclosed |
| US-3932419-A | QUINOLINE DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, SMN1; SMN2, ADRM1 | TSHR 3960/4885MCOLN3 2558/4885PTGES2 3788/4885 |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | TSHR 2787/4885MCOLN3 1952/4885PTGES2 3247/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TSHR 832/4885MCOLN3 967/4885PTGES2 4148/4885 |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, KRAS, BRAF | TSHR 672/4885MCOLN3 2200/4885PTGES2 4075/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | TSHR 2794/4885MCOLN3 1921/4885PTGES2 3267/4885 |
| US-12404248-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | TSHR 3866/4885MCOLN3 4460/4885PTGES2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.